GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: MASH stopped being a problem at week 43 — 64 comments in the full submission. View in context.
1.2k
c/survodutide·submitted 1 year ago by u/quant_not_qual

small win: MASH stopped being a problem at week 43

Discussionbranch of 7 comments

small win: MASH stopped being a problem at week 43. Full detail below, and I have tried to keep the editorialising out of it. Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other. Histological endpoints in this field are…

Read the full submission and all 64 comments →

This branch

7 comments, started 1 year ago
u/liver_enzyme_lizMOD122 points·1 year ago

Independent result logged. There are almost none for this compound, so it is genuinely valuable.

replysharereportpermalink
u/cesar_ivaturi50 points·1 year ago

Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.

replysharereportpermalink
u/quant_not_qualOP0 points·1 year ago

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

replysharereportpermalink
u/quant_not_qualOP31 points·1 year ago

Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.

Agreed — and the endpoint definitions are where the actual claim lives.

replysharereportpermalink
u/quant_not_qualOP-23 points·1 year ago

Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.

replysharereportpermalink
u/clara_restrepo10 points·1 year ago

dual GLP-1 and glucagon agonist, and the glucagon arm is the story

replysharereportpermalink
[deleted]45 points·1 year ago

[deleted]

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →